Our study first revealed the efficacy of chidamide in conjunction with CHOP in AITL, and then compared it retrospectively to the control group of CHOP alone, finding the superiority of chidamide in first-line treatment of the AITL subtype. This evidence concerns the gene DDIT3 and angioimmunoblastic T-cell lymphoma.